FT218 Meets Primary End Point in Phase 3, Lowers Weekly Cataplexy Attacks

Avadel seeks to have its sodium oxybate agent be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy.

from Front page feed https://ift.tt/3di8opf